Mexico’s Senate majority leader, Ricardo Monreal, has cast doubt on the passage of the U.S.-Mexico-Canada Agreement (USMCA) after citing concerns about higher pharmaceutical pricing due to USMCA’s new patent rules. That comes on top of potential U.S. Congressional hurdles and the Canadian elections as potential blocks to USMCA coming into force. Mexico’s pharmaceutical imports reached $6.11 billion in 2018 with 25.0% accounted for by the U.S. Suppliers from the U.S., including Roche and Eli Lilly, saw shipment growth lag that of competitors from China and India.